Purchase by Sanjay Shukla of 1422 shares of ATyr Pharma

About 67% of ATyr Pharma's investor base is looking to short. The analysis of current outlook of investing in ATyr Pharma suggests that many traders are alarmed regarding ATyr Pharma's prospects. The current market sentiment, together with ATyr Pharma's historical and current headlines, can help investors time the market. In addition, many technical investors use ATyr Pharma stock news signals to limit their universe of possible portfolio assets.
  
Filed transaction by Atyr Pharma Inc director. General open market or private purchase of non-derivative or derivative security

Read at macroaxis.com
ATyr insider trading alert for perchase of common stock by Sanjay Shukla, President and CEO, on 13th of November 2023. This event was filed by Atyr Pharma Inc with SEC on 2023-11-13. Statement of changes in beneficial ownership - SEC Form 4

ATyr Pharma Fundamental Analysis

We analyze ATyr Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ATyr Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ATyr Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

EBITDA

EBITDA Comparative Analysis

ATyr Pharma is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

ATyr Pharma Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ATyr Pharma stock to make a market-neutral strategy. Peer analysis of ATyr Pharma could also be used in its relative valuation, which is a method of valuing ATyr Pharma by comparing valuation metrics with similar companies.

Peers

ATyr Pharma Related Equities

XFORX4 Pharmaceuticals   11.43   
0%
100.0%
TERNTerns Pharmaceuticals   7.82   
0%
68.0%
HOOKHookipa Pharma   6.90   
0%
60.0%
MREOMereo BioPharma   4.71   
0%
41.0%
ABOSAcumen Pharmaceuticals   2.73   
0%
23.0%
INZYInozyme Pharma   2.64   
0%
23.0%
PDSBPDS Biotechnology   1.90   
0%
16.0%
DAWNDay One   1.33   
0%
11.0%
AMLXAmylyx Pharmaceuticals   0.00   
0%
0%
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in census.
You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Other Consideration for investing in ATyr Stock

If you are still planning to invest in ATyr Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ATyr Pharma's history and understand the potential risks before investing.
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity